Study on precise drug use in postoperative patients with peripheral blood mononuclear cell immunosuppressive concentration combined with gene polymorphism after transplantation

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400082530

Enrollment

Unknown

Registered

2024-04-01

Start date

2024-04-01

Completion date

Unknown

Last updated

2024-04-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Organ transplantation

Interventions

group with good prognosis:none

group with adverse prognosis:none

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1: Single organ transplant recipients who have received liver or kidney transplantation for the first time in our hospital 2: Postoperative use of tacrolimus, mycophenolate mofetil, or mycophenolate sodium enteric coated tablets for immunosuppressive regimen 3: Age 18-75 4: Patients who undergo regular blood drug concentration testing in our hospital

Exclusion criteria

Exclusion criteria: 1: Electronic medical records are severely missing 2: Multiple organ transplantation 3: Patients with ABO blood group incompatibility between donor and recipient 4: Patients who switch to immunosuppressive regimens midway

Design outcomes

Primary

Measure	Time frame
Tacrolimus concentration in peripheral blood PBMC;Mycophenolic acid concentration in peripheral blood PBMC;	—

Secondary

Measure	Time frame
Polymorphism of target pathway genes;	—

Countries

China

Contacts

Public ContactYang Na

Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School,Nanjing University

shillingyang@163.com+86 181 1516 1056

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026